Consider buying Hims & Hers Health (HIMS), as recent fears about competition in the weight loss market appear to be an overreaction. The market overlooks that HIMS is a diversified telehealth platform, with over 70% of its revenue coming from established streams like erectile dysfunction and mental health treatments. Its primary advantage is a unique all-in-one subscription that bundles the doctor's visit and medication, removing financial risk for consumers. Competitors like Amazon (AMZN) have a weaker model, as their lower prices exclude the significant hidden cost and inconvenience of a separate doctor's consultation. This superior, risk-free business model provides HIMS with a strong competitive moat, presenting a compelling investment opportunity.

Hims & Hers Health, Inc. (HIMS)

• The podcast host is very bullish on HIMS and believes the recent negative sentiment ("FUD") surrounding competition in the GLP-1 weight loss drug market is overblown.
• Diversified Business: The market incorrectly views HIMS as only a GLP-1 company. The host argues that the stock's movement is disproportionately tied to GLP-1 news.
  • The host estimates that GLP-1s currently account for only 25% of HIMS's revenue.
  • For 2025, HIMS guides for $725 million in weight loss revenue out of a $2.35 billion total, which would be about 30% of the business.
  • HIMS has other major, established revenue streams that are often overlooked, including:
    • Erectile Dysfunction (ED) medication
    • Mental health (anti-anxiety/SSRI medication)
    • Hair loss treatments (shampoos, etc.)
• Weight Loss Strategy: The company's weight loss business is not just compounded GLP-1s.
  • A significant portion (estimated at $100 million+ and growing) comes from oral weight loss pills like Metformin-based solutions.
  • HIMS is also selling its own generic version of Liraglutide, a GLP-1 drug that is now off-patent.
• Business Model Innovation: The core of the bullish argument is HIMS's unique, all-inclusive business model, which sets it apart from competitors.
  • The monthly subscription fee (e.g., $199 for GLP-1s) bundles the medication, the initial doctor consultation, and any necessary follow-up appointments.
  • Crucially, if a customer does not get a prescription after the consultation, they do not pay. This removes the financial risk for the consumer, which is a "magical" and "zero to one" innovation in healthcare.
• Brand & Growth:
  • HIMS is a well-established brand in the U.S. due to extensive TV, radio, and digital advertising, giving it legitimacy over smaller, unknown online providers.
  • The company has high customer satisfaction, with app store ratings of 4.7 (Apple) and 4.6 (Google).
  • The business showed strong resilience and a return to growth in Q3 after ending its partnership with Novo Nordisk in Q1, demonstrating its ability to adapt.

Takeaways

• The market's fear about competition from companies like Amazon may be an overreaction, potentially presenting a buying opportunity for investors who believe in HIMS's long-term strategy.
• Investors should evaluate HIMS not just as a weight loss company, but as a diversified telehealth platform with a strong brand and multiple revenue streams.
• The key competitive advantage to watch is the all-inclusive business model. As long as competitors fail to bundle the doctor visit and medication seamlessly, HIMS maintains a powerful moat. This model removes the friction and hidden costs for consumers, which is a major differentiator.

Amazon (AMZN)

• The market is reacting to news of Amazon launching a GLP-1 offering (Wegovy) for $149 a month, which is cheaper than HIMS's $199 a month price point.
• The host is bearish on Amazon's ability to disrupt HIMS, calling the fear "FUD" and comparing it to past failed Amazon ventures like the Fire Phone.
• Flawed Business Model: The primary weakness in Amazon's offering is that the $149 price does not include the doctor visit.
  • Customers must obtain a prescription separately, which adds significant friction, inconvenience, and cost.
  • A separate doctor visit can cost $200+, and there is no guarantee the doctor will even prescribe the medication. The patient bears this cost regardless of the outcome.
  • This model is the same as other competitors like Cost Plus Drugs and Lili Direct, and it fails to solve the core problem of easy, risk-free access for the consumer.

Takeaways

• Amazon's lower price point is misleading because it excludes the significant "hidden costs" and hassle of obtaining a prescription.
• While Amazon is a formidable competitor in many industries, its current pharmacy model is not structured to effectively compete with the convenient, all-in-one service offered by companies like HIMS and LifeMD.
• Investors should be cautious about assuming Amazon will automatically dominate the telehealth prescription market, as its model lacks the key business model innovation that is driving customer adoption for HIMS.